A number of other analysts have also weighed in on VERU. Zacks Investment Research raised shares of Veru from a sell rating to a buy rating and set a $1.50 target price on the stock in a report on Tuesday, February 19th. CIBC assumed coverage on shares of Veru in a report on Wednesday, March 20th. They set an outperform rating and a $5.00 target price on the stock. HC Wainwright reaffirmed a buy rating and set a $4.50 target price on shares of Veru in a report on Wednesday, January 23rd. Maxim Group set a $6.00 target price on shares of Veru and gave the stock a buy rating in a report on Thursday, February 14th. Finally, Oppenheimer assumed coverage on shares of Veru in a report on Tuesday, March 19th. They set an outperform rating and a $5.00 target price on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Veru currently has a consensus rating of Buy and an average target price of $4.40.
Veru stock opened at $1.60 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.30 and a current ratio of 1.58. The company has a market cap of $100.37 million, a P/E ratio of -4.10 and a beta of 0.88. Veru has a 1-year low of $1.18 and a 1-year high of $2.37.
In other news, insider Mitchell Shuster Steiner sold 49,899 shares of the stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $1.53, for a total value of $76,345.47. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders bought 38,681 shares of company stock worth $53,206 and sold 109,545 shares worth $163,245. 29.50% of the stock is owned by corporate insiders.
Several large investors have recently modified their holdings of VERU. Dimensional Fund Advisors LP increased its holdings in shares of Veru by 328.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 102,909 shares of the company’s stock worth $146,000 after buying an additional 78,909 shares during the last quarter. Vanguard Group Inc boosted its stake in shares of Veru by 1.2% in the 3rd quarter. Vanguard Group Inc now owns 1,199,963 shares of the company’s stock valued at $1,704,000 after purchasing an additional 13,650 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Veru by 9.3% in the 4th quarter. BlackRock Inc. now owns 128,766 shares of the company’s stock valued at $180,000 after purchasing an additional 10,956 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Veru by 115.4% in the 4th quarter. Geode Capital Management LLC now owns 215,601 shares of the company’s stock valued at $301,000 after purchasing an additional 115,506 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Veru in the 1st quarter valued at $95,000. 8.75% of the stock is currently owned by hedge funds and other institutional investors.
Veru Company Profile
Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
Further Reading: Are all No-Load Funds Equal?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.